Triptorelin

Triptorelin is a synthetic decapeptide analogue of gonadotropin-releasing hormone (GnRH), the hypothalamic peptide that normally drives the entire reproductive hormone axis. Like other GnRH agonist analogues, Triptorelin has higher receptor affinity and longer half-life than endogenous GnRH, and its paradoxical biological profile - initial stimulation followed by sustained suppression - makes it a uniquely powerful research tool.

Under normal physiology, GnRH is released from the hypothalamus in pulses every 60-90 minutes. These pulses stimulate pituitary gonadotrophs to release LH (luteinising hormone) and FSH (follicle-stimulating hormone) in corresponding pulses, which in turn stimulate gonadal production of testosterone (in males) and estrogen + progesterone (in females). This entire axis depends on the pulsatile nature of GnRH - sustained GnRH stimulation causes receptor downregulation rather than sustained stimulation.

Triptorelin exploits this physiology. Initial administration produces an acute LH and FSH surge (the "flare" effect) as the pituitary responds to the agonist signal. Within 1-3 weeks of continuous or near-continuous exposure, GnRH receptors on the pituitary are downregulated, and the LH/FSH surge ceases - resulting in castration-level sex hormone suppression. This "chemical castration" is clinically used in prostate cancer treatment, precocious puberty, and endometriosis.

Within the research peptide community, Triptorelin has attracted interest for a completely different application: resetting the hypothalamic-pituitary-gonadal axis after suppression from anabolic steroids or other compounds. A single-dose protocol (typically 100 mcg one-time) is hypothesised to produce an acute LH surge sufficient to stimulate Leydig cell function and "kickstart" the suppressed axis. Research data on this specific single-dose application is limited, but the endocrinological rationale has made it an active area of investigation.